Development of a cell penetrating peptide, Omomyc, targeting the Myc oncoprotein for cancer treatment.

Founded in 2014, Peptomyc is a spin-off of the Vall d’Hebron Institute of Oncology and the Catalan Institution for Research and Advanced Studies. Peptomyc is focused on the development of a new generation of cell penetrating peptides targeting the MYC oncoprotein for cancer treatment.

Fund

Alta Life Sciences Spain I FCR

Sector

Therapeutics

Website

Exit year